FIELD: medicine, ophthalmology, in particular. SUBSTANCE: immunohistochemical analysis of cells of removed tumor is conducted, percentage of cells expressing Bax with reference to total number of tumor cells in field of vision is established. If their presence exceed 20% and more probability of progress of metastasis is predicted in 80% of cases. EFFECT: increased accuracy and objectivity of clinical course of uvea melanoma. 1 dwg
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTING METASTASES OF UVEAL MELANOMA BASED UPON APOPTOSIS MARKERS BAX AND BCL-2 | 2003 |
|
RU2242766C1 |
METHOD FOR PREDICTING UVEAL MELANOMA METASTASIS FORMATION ON THE BASIS OF BAX AND KI-67 MARKERS | 2003 |
|
RU2240560C1 |
METHOD FOR PREDICTING UVEAL MELANOMA METASTASIS SPREAD WITH APOPTOSIS MARKERS BAX AND BCL-2 | 2003 |
|
RU2244934C2 |
METHOD PREDICTING CLINICAL COURSE OF UVEA MELANOMA BASED ON APOPTHOSIS MARKER p53 | 2002 |
|
RU2208789C1 |
METHOD FOR PREDICTION OF SURVIVAL RATE AFTER ENUCLEATION WITH UVEAL MELANOMA DEVELOPED TO EQUATOR | 2024 |
|
RU2822319C1 |
METHOD OF SIMULTANEOUS VERIFICATION AND PREDICTION OF COURSE OF UVEAL MELANOMA | 2006 |
|
RU2337362C1 |
METHOD OF SIMULTANEOUS VERIFICATION OF UVEAL MELANOMA COURSE FORECAST | 2006 |
|
RU2327420C1 |
METHOD FOR PREDICTING CLINICAL FLOW OF UVEAL MELANOMA | 2001 |
|
RU2193200C1 |
METHOD FOR PREDICTING CLINICAL COURSE OF UVEAL MELANOMA DEVELOPMENT | 2001 |
|
RU2197731C2 |
METHOD FOR PREDICTING CLINICAL COURSE OF UVEAL MELANOMA DEVELOPMENT | 1999 |
|
RU2157998C1 |
Authors
Dates
2003-07-20—Published
2002-10-28—Filed